Sep 08, 2022 / 03:00PM GMT
Mohit Bansal - Wells Fargo Securities, LLC, Research Division - Senior Equity Analyst
Thank you very much for joining us today. My name is Mohit Bansal. I'm one of the biopharma analysts here at Wells Fargo. And with us next, we have the Regeneron management team with us. We have Bob Landry, the CFO of the company; Ryan Crowe, the Head of IR of the company. Thank you very much, Bob and Ryan, for joining us. And with that, I'll hand it over to you, Bob.
Robert E. Landry - Regeneron Pharmaceuticals, Inc. - Executive VP of Finance & CFO
Okay. Ryan, why don't you open up with an FLS?
Ryan Crowe - Regeneron Pharmaceuticals, Inc. - VP of IR
Absolutely. So today's discussion may contain forward-looking statements, which may contain -- actual results may differ from those forward-looking statements. A discussion of our risks and uncertainties may be found in our SEC disclosure documents. And any forward-looking statements, we're not obligated to update them at any time.
Robert E. Landry -
Regeneron Pharmaceuticals Inc at Wells Fargo Healthcare Conference Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers